GLP 1 Receptor Agonists to have better outcomes Than DPP4 Inhibitors
A recent study suggests that the use of GLP-1 receptor agonists was associated with better outcomes compared with the use of DPP-4 inhibitors among patients with type 2 diabetes and advanced-stage chronic kidney disease. The study findings were published in the JAMA Network Open on March 07, 2022.
Chronic kidney disease (CKD) and end-stage kidney disease (ESKD) are contributors to the health burden and are associated with increased mortality and cardiovascular events. Type 2 diabetes is the most common cause of CKD, and both diabetes and CKD are associated with increased all-cause mortality and increased rates of infection and cardiovascular events.
For more information check out the full story on the link below:
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)